11. Stock-Based Compensation

2014 Equity Incentive Plan

On October 3, 2014, the stockholders approved the 2014 Equity Incentive Plan. On June 20, 2017, the Company’s Board of Directors amended the 2014 Equity Incentive Plan, or the Amended and Restated 2014 Plan.

The Amended and Restated 2014 Plan, as amended, provides for the grant of incentive and non-statutory stock options, stock appreciation rights, restricted stock and stock unit awards, performance units, stock grants and qualified performance-based awards. The total number of shares authorized was 4,474,683 shares. As of June 7, 2024, in connection with the creation of the 2024 Equity Incentive Plan, or the 2024 Plan, no additional awards will be made under the Amended and Restated 2014 Plan, as amended.

As of June 30, 2026, there were 3,221,520 shares of common stock subject to outstanding awards under the Amended and Restated 2014 Plan, as amended. 

2017 Equity Incentive Plan

On August 10, 2017, ArTara Subsidiary, Inc. (a predecessor of the Company), or Private ArTara, along with its Board of Directors and its stockholders approved the ArTara Therapeutics, Inc. 2017 Equity Incentive Plan, or the 2017 Plan, to enable Private ArTara and its affiliates to recruit and retain highly qualified personnel and to incentivize personnel for productivity and growth.

The total number of shares authorized under the 2017 Plan was 2,000,000 for the issuance of stock options, stock appreciation rights, restricted stock and restricted stock units, or RSUs, to among others, members of the Board of Directors, employees, consultants and service providers to the Company and its affiliates. As of January 9, 2020 no additional awards will be made under the 2017 Plan.

As of June 30, 2026, there were 134,328 shares of common stock subject to outstanding awards under the 2017 Plan.

2020 Inducement Plan

On March 26, 2020, the Compensation Committee of the Board of Directors, or the Compensation Committee, approved the 2020 Inducement Plan, or the 2020 Plan, in order to award non-statutory stock options, restricted stock awards, restricted stock unit awards and other stock-based awards to persons not previously an employee or director of the Company, or following a bona fide period of non-employment, as an inducement material to such persons entering into employment with the Company. The Compensation Committee also adopted a form of stock option grant notice and stock option agreement and forms of restricted stock unit grant notice and restricted stock unit agreement for use with the 2020 Plan.

The 2020 Plan provided for a total of 600,000 shares for the issuance of the Company’s common stock. On March 3, 2025, the Compensation Committee approved a Certificate of First Amendment to the 2020 Plan, or the Amended 2020 Plan, to increase the number of shares provided for under the Amended 2020 Plan by 600,000 shares to 1,200,000 shares.

As of June 30, 2026, there were 980,098 shares of common stock subject to outstanding awards and 185,740 shares of common stock available for future issuance under the Amended 2020 Plan. 

2024 Equity Incentive Plan

On June 7, 2024, the stockholders approved the 2024 Plan. The 2024 Plan provided for the grant of 1,500,000 shares of common stock for stock options, stock appreciation rights, restricted stock, RSUs, performance units, performance shares and other stock and cash awards. On June 11, 2025, the stockholders approved an amendment to the 2024 Plan increasing the number of shares available for grant under the 2024 Plan by 2,800,000 shares to 4,300,000 shares. On June 12, 2026, the stockholders approved an amendment to the 2024 Plan, or the Amended 2024 Plan, increasing the number of shares available for grant under the Amended 2024 Plan by 5,000,000 shares to 9,300,000 shares.

Terms of the stock awards, including vesting requirements, are determined by the Board of Directors, or the Compensation Committee thereof, subject to the provisions of the Amended 2024 Plan.

As of June 30, 2026, there were 4,129,936 shares of common stock subject to outstanding awards and 5,093,541 shares of common stock available for future issuance under the Amended 2024 Plan.

2024 Employee Stock Purchase Plan

On June 7, 2024, the stockholders of the Company approved the 2024 Employee Stock Purchase Plan, or the 2024 ESPP. The number of shares authorized under the 2024 ESPP is 1,000,000.

As of June 30, 2026, the number of shares available for issuance under the 2024 ESPP was 1,000,000. During the three and six months ended June 30, 2026, no shares were issued under the 2024 ESPP.  

Restricted Stock Units

The following table summarizes restricted stock unit activity for the six months ended June 30, 2026:

The fair value of RSUs is amortized on a straight-line basis over the requisite service period of the respective awards. As of June 30, 2026, the unamortized value of RSUs was $2,549. As of June 30, 2026, the weighted average remaining amortization period was 2.09 years. As of June 30, 2026 and December 31, 2025, 289,500 RSUs have vested but have not yet been settled into shares of the Company’s common stock.

During the six months ended June 30, 2026, the Company issued 166,198 shares of the Company’s common stock from the net settlement of 217,475 RSUs. The Company paid $298 in connection with the net share settlement of these RSUs.

Stock Options

The following table summarizes stock option activity for the six months ended June 30, 2026:

The weighted average grant date fair value per share of the options granted during the six months ended June 30, 2026 and 2025 was $3.46 and $3.02, respectively. As of June 30, 2026, there was approximately $10,873 of unrecognized stock-based compensation for unvested stock option grants, which is expected to be recognized over a weighted average period of 2.72 years. The total unrecognized stock-based compensation cost will be adjusted for actual forfeitures as they occur.

Summary of Stock-Based Compensation Expense

The following tables summarize total stock-based compensation costs recognized:

Stock-based compensation expense was reflected within the condensed consolidated statements of operations and comprehensive loss as: